Latest News
May 17, 2021
Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)
Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes
May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes